AC
Armistice Capital Portfolio holdings
AUM
$2.64B
This Quarter Return
+3.1%
1 Year Return
+0.99%
3 Year Return
+16.29%
5 Year Return
+18.04%
10 Year Return
+34.8%
AUM
$3.76B
AUM Growth
+$3.76B
(-0.26%)
Cap. Flow
-$288M
Cap. Flow
% of AUM
-7.67%
Top 10 Holdings %
Top 10 Hldgs %
29.5%
Holding
431
New
137
Increased
85
Reduced
85
Closed
95
Top Buys
| 1 |
Incyte
INCY
|
$111M |
| 2 |
Cytokinetics
CYTK
|
$107M |
| 3 |
Coca-Cola
KO
|
$46M |
| 4 |
Grifois
GRFS
|
$44.4M |
| 5 |
Humana
HUM
|
$43.4M |
Top Sells
| 1 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$117M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$80.1M |
| 3 |
Freshpet
FRPT
|
$72.9M |
| 4 |
Amazon
AMZN
|
$59.5M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
$53.6M |
Sector Composition
| 1 | Healthcare | 68.13% |
| 2 | Consumer Staples | 11.13% |
| 3 | Consumer Discretionary | 10.21% |
| 4 | Technology | 7.08% |
| 5 | Communication Services | 1.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
PTC Therapeutics
PTCT
$3.92B
| $197M | 2.61% | 6,764,000 -100,000 | -1% | -$2.91M |
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $141M | 1.87% | 1,023,739 -24,261 | -2% | -$3.35M |
|
|
3
Incyte
INCY
$16.5B
| $125M | 1.65% | 2,187,181 +1,951,181 | +827% | +$111M |
|
4
Supernus Pharmaceuticals
SUPN
$2.53B
| $122M | 1.62% | 3,572,000 -1,078,000 | -23% | -$36.8M |
|
|
5
Cytokinetics
CYTK
$4.23B
| $107M | 1.42% | +1,525,688 | New | +$107M |
|
6
argenx
ARGX
$43.6B
| $104M | 1.38% | 264,000 -54,000 | -17% | -$21.3M |
|
|
DCPH
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $92.8M | 1.23% | 5,900,000 +700,000 | +13% | +$11M |
|
8
Agios Pharmaceuticals
AGIO
$2.19B
| $86.7M | 1.15% | 2,964,000 -560,000 | -16% | -$16.4M |
|
9
Immunovant
IMVT
$2.56B
| $69.9M | 0.93% | 2,164,000 +728,000 | +51% | +$23.5M |
|
10
Sanofi
SNY
$121B
| $63.1M | 0.84% | 1,298,000 +262,000 | +25% | +$12.7M |
|
11
Aurinia Pharmaceuticals
AUPH
$1.58B
| $61.4M | 0.81% | 12,260,000 +2,724,000 | +29% | +$13.6M |
|
12
Dentsply Sirona
XRAY
$2.85B
| $58M | 0.77% | 1,747,055 -148,945 | -8% | -$4.94M |
|
13
Travere Therapeutics
TVTX
$1.56B
| $57.8M | 0.77% | 7,500,000 +116,000 | +2% | +$894K |
|
14
Medtronic
MDT
$119B
| $55.1M | 0.73% | 632,359 +24,359 | +4% | +$2.12M |
|
15
Orthofix Medical
OFIX
$592M
| $53.7M | 0.71% | 3,700,000 +100,000 | +3% | +$1.45M |
|
|
NVRO
16
DELISTED
NEVRO CORP.
NVRO
| $52.3M | 0.69% | 3,624,000 +448,000 | +14% | +$6.47M |
|
17
Novo Nordisk
NVO
$251B
| $51.4M | 0.68% | 400,000 +4,000 | +1% | +$514K |
|
18
Exact Sciences
EXAS
$8.98B
| $50.5M | 0.67% | 730,648 -41,173 | -5% | -$2.84M |
|
19
DocuSign
DOCU
$15.5B
| $47.9M | 0.63% | 803,675 +235,675 | +41% | +$14M |
|
20
Ironwood Pharmaceuticals
IRWD
$214M
| $47M | 0.62% | 5,400,000 -300,000 | -5% | -$2.61M |
|
|
21
Coca-Cola
KO
$297B
| $46M | 0.61% | +752,662 | New | +$46M |
|
22
Madrigal Pharmaceuticals
MDGL
$9.76B
| $44.9M | 0.6% | 168,000 +118,000 | +236% | +$31.5M |
|
|
23
Grifois
GRFS
$6.78B
| $44.4M | 0.59% | +6,648,000 | New | +$44.4M |
|
24
Biohaven
BHVN
$1.63B
| $43.7M | 0.58% | 799,263 -700,737 | -47% | -$38.3M |
|
25
Kura Oncology
KURA
$686M
| $43.7M | 0.58% | 2,048,000 -176,000 | -8% | -$3.75M |
|